


Method name	Evaluation of the efficacy of drugs for the treatment of inflammatory bowel disease
Organ system	Bowel
Subject area	Drug development
Area of application	Formulation development
Relation of the method to the 3Rs	Replacement & Reduction, Prediction of drug efficacy in the treatment of inflammatory bowel disease
Figure	
Brief description	The method is based on the combination of the cell types Caco-2 and MDM. By measuring TEER levels and cytokine release, initial conclusions can be drawn about the efficacy of a drug for treating inflammatory bowel disease. Additional viability tests (MTT/LDH) or excessive barrier collapse (measured by TEER) provide conclusions about the safety of a formulation.
Contact person 1	Sabrina Schnur Saarland University sabrina.schnur@uni-saarland.de
Contact person 2	Prof. Marc Schneider Saarland University marc.schneider@uni-saarland.de
Contact person 3	Dr. Marius Hittinger PharmBioTec gGmbH m.hittinger@pharmbiotec.de
Theme-based funding	EFRE project, E-Bio-Barriere
Publication	Schnur, Sabrina. 2022. "Inflammatory bowel disease addressed by Caco-2 and monocyte-derived macrophages: an opportunity for an in vitro drug screening assay." In vitro models. Schnur, Sabrina. 2023. "The Potential of Epigallocatechin-3-gallate (EGCG) as Complementary Medicine for the Treatment of Inflammatory Bowel Disease." Pharmaceuticals.